Zentalis Pharmaceuticals Investor Presentation — August 2022

Document content

C O R P O R AT E P R E S E N TAT I O N

A u g u s t 2 0 2 2Forward -Looking Statements and Disclaimer

Zentalis Pharmaceuticals, Inc.(“we,” “us,” “our,” “Zentalis” orthe“Company”) cautions that thispresentation (including oral commentary that accompanies thispresentation) contains forward -looking

statements within the meaning ofthe U.S.Private Securities Litigation Reform Actof1995 .Allstatements contained inthis presentation that donotrelate tomatters ofhistorical fact should be

considered forward -looking statements, including without limitation statements regarding thetarget profiles and potential benefits ofour product candidates, including asamonotherapy and/or in

combination ;clinical and regulatory progress ofour product candidates, including the estimated timing ofthe initiation ofclinical trials and data readouts ;the market potential ofour product

candidates ;our milestones ;and the potential ofour collaborations areforward -looking statements, aswell asstatements that include thewords “potential,” “design,” “expect,” “intend,” “plan,”

“believe,” “estimate,” “may,” and similar statements ofafuture orforward -looking nature .These statements areneither promises norguarantees, butinvolve known and unknown risks, uncertainties

and other important factors that may cause ouractual results, performance orachievements tobematerially different from any future results, performance orachievements expressed orimplied by

theforward -looking statements, including, butnotlimited to,thefollowing :theoutbreak ofthenovel coronavirus disease, COVID -19,hasadversely impacted and may continue toadversely impact our

business, including ourpreclinical studies and clinical trials ;ourlimited operating history, which may make itdifficult toevaluate ourcurrent business and predict ourfuture success and viability ;we

have and expect tocontinue toincur significant losses ;ourneed foradditional funding, which may notbeavailable ;oursubstantial dependence onthesuccess ofourlead product candidate ;failure to

identify additional product candidates and develop orcommercialize marketable products ;theearly stage ofour development efforts ;potential unforeseen events during clinical trials could cause

delays orother adverse consequences ;risks relating tothe regulatory approval process orongoing regulatory obligations ;failure toobtain U.S.orinternational marketing approval ;our product

candidates may cause serious adverse side effects ;interim, initial, “topline”, and preliminary data from ourclinical trials that weannounce orpublish from time totime may change asmore patient data

become available and aresubject toaudit and verification procedures that could result inmaterial changes inthefinal data ;inability tomaintain ourcollaborations, orthefailure ofthese collaborations ;